Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study
Abstract Background Renin–angiotensin–aldosterone system (RAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors are key treatments for diabetic kidney disease. However, their independent and combined effects on end-stage kidney disease (ESKD) and mortality remain unclear. This study...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-025-02846-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|